Advanced searches left 3/3

Dyspepsia - Crossref

Summarized by Plex Scholar
Last Updated: 25 July 2022

* If you want to update the article please login/register

Factors associated with mood disorders and the efficacy of the targeted treatment of functional dyspepsia: A randomized clinical trial

History Patients with functional dyspepsia are often accompanied by mood disorders. Patients with FDI and acid reflux were treated with flupentixol and melitracen, as well as acid-suppressive therapy, and those without acid reflux did not receive AST. Patients with FD without MDs were randomly administered H2RAs or PPIs. Patients with a high GI score and low education were prone to MDs in FD patients with high GI score and low education. (72. 22% vs. 41. 67% and 72. 22% vs. 38. 9%, all P 0. 05) at week 2, the remission rate of overall GI symptoms and depression was significantly higher in group B than in group A and C [GI: 72. 32% vs. 41. 7 percent and 72. 22% vs. 41. 8 percent and 72. 79 percent vs. 38. 94% vs. 38. 94%; depression: 72. 22% vs. Nevertheless, the remission rate of general GI symptoms in group E was much higher than that in group D [60. 29% vs. 42. 65%], P 0. 05].

Source link: https://doi.org/10.3389/fmed.2022.859661


Effect of Acotiamide and Esomeprazole combination therapy on Functional Dyspepsia symptoms in comparison with Acotiamide or Esomeprazole Monotherapy: A Prospective Observational Study

Aim: The aim of this study was to determine the effects of acotiamide and esomeprazole combination therapy in reducing Functional Dyspepsia-related signs in comparison to acotiamide or esomeprazole monotherapy. For a period of six weeks, Group 1 received acotiamide, group 2 received esomeprazole, and group 3 received acotiamide plus esomeprazole combination therapy. In both the three treatment groups, there was a statistically significant improvement in symptoms assessment scale - Epigastric pain syndrome, Postprandial distress syndrome, and Total Abdominal Symptom scores from baseline to 6 weeks. Conclusion: Acotiamide and esomeprazole combined therapy was helpful in lowering symptoms in patients with FD at the end of 6 weeks in patients with FD at the end of 6 weeks, as compared to monotherapy with either of the drugs.

Source link: https://doi.org/10.52711/0974-360x.2022.00430


Smaller CO2 injection volume and lower gastric pressure induce bothersome symptoms in drug-resistant functional dyspepsia patients with less frequent belching

Background The relationship between troubling signs and gastric pressure or CO 2 injection volumes in drug-resistant functional dyspepsia patients remains unclear; therefore, it was investigated in both drug-resistant FD and non-FD patients. Methods Thirty drug-resistant FD patients and 30 non-FD patients were recruited along with 30 other non-FD patients. Following the CO 2 injection, patients immediately experienced abdominal pain and bothersome signs, including gastric pressure and CO 2 injection volume. In drug-resistant FD patients, the upper abdomen began with a significant lower gastric pressure and a much smaller CO 2 injection volume than in non-FD patients. In the drug-resistant FD group, the incidence of belching was significantly lower than in the non-FD group. Bothersome signs in drug-resistant FD patients develop at a lower gastric pressure and smaller CO 2 injection volume than in non-FD patients.

Source link: https://doi.org/10.1371/journal.pone.0271456


Chinese Herbal Medicine for Functional Dyspepsia With Psychological Disorders: A Systematic Review and Meta-Analysis

Background and Aims Functional dyspepsia is closely related to gut-u2013brain interaction disorder, which is characterized by the interaction of digestive symptoms and central nervous system dysregulation. Patients with concurrent psychological disorders may have a positive concurrent effect in the treatment of FD. Methods The PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure, Wang Data, Beijing, China, and the China Science and Technology Journal Database were all searched for randomized controlled trials of FD treated with CHM. The incidence of CHM in the treatment of FD was higher than that in the placebo group [relative risk = 1. 76; 95% confidence interval 0. 1]]. CHM in the treatment of FD was higher than the control group's [RR = 1. 17; 95% CI, P 0. 0001]]. 0: 0. 14; 95% CI; Z = 0. 33; P = 0. 73]; M = 0. 30; P = 0. 19; P = 0. 19; Z = 0. 44; P = 0. 70] The results of the two portions of the meta-analysis revealed no significant adverse reactions between the experimental group and the control group, with no significant difference in the adverse reactions between the experimental group and the control group [MD = 0. 14; 95% CI; 95% CI ; P = 0. 14; Z = 0. 14; Z = 0. 14; Z = 0. 14; P = 0. 34; P = 0. 44; Z = 0. 14; P = 0. 30; P = 0. 38; Z = 0. 19]; Z = 0. 19]; P = 0. 19]; P = 0. 20; P = 0. 19; P = 0. 19; P = 0. 34; P = 0. 47; P = 0. 73; P = 0. 44; [PM = 0. 14; 95% CI; P = 0. 19; Z = 0. 33; P = 0. 39; P = 0. 74; [PR; Z = 0. 33; P = 0. 19; P = Conclusion The current research shows that CHM therapy has a high likelihood and success in reducing the symptoms of FD and improving the psychological disorders of anxiety and depression in patients with FD.

Source link: https://doi.org/10.3389/fnins.2022.933290


Repeated administration of ghrelin to patients with functional dyspepsia: its effects on food intake and appetite.

Objective We tried to determine the clinical response to repeated ghrelin administration in patients with anorexia due to medical disorders, such as functional dyspepsia. The exception of anorexia nervosa was identified with functional anorexia, including FD and other eating disorders, but no one was diagnosed with functional anorexia, including anorexia nervosa; 2 were lean body mass index BMI 22 kg/m 2; and 3 reported reduced FI. Infusion of ghrelin 3 bcg/kg for 30 min twice a day before breakfast and dinner for two weeks. We investigated the effects of ghrelin administration on FI, appetite, hormones, and metabolic measurements. Conclusions These findings reveal that the ghrelin administration is safe and that it has stimulatory effects on appetite in patients with FD. To determine the effectiveness of ghrelin therapy for anorexia-related disorders, further research is required.

Source link: https://doi.org/10.1530/eje-07-0768


Herbal Medicines in the Treatment of Dyspepsia: An Overview

This paper examines the efficacy of herbal drugs for treating dyspepsia in humans and animals. In each database, the search terms used consisted of the two key terms describing the condition and subtypes plus each of the therapy terms. We included all human and animal studies on the effects of herbal medicines on dyspepsia symptoms, including the key cause of dyspepsia syndromes. Only relevant clinical trials with scientifically validated protocols can determine whether herbal medications can be used as viable alternatives to the common pharmaceutical drugs used to treat dyspepsia symptoms.

Source link: https://doi.org/10.1055/a-1580-7782


A Randomized Controlled Study of Efficacy and Safety Profile of Levosulpiride and Itopride in Functional Dyspepsia

ABSTRACT Introduction Dyspepsia is a clinical issue of significant importance for the healthcare system due to its widespread prevalence and persistent and recurrent symptomatic causes. Earlier dyspepsia was referred to as a heterogeneous group of signs in the upper abdomen and retrosternal that are related to meal ingestion and include heartburn, epigastric pain, epigastric burning, postprandial fullness/distension, early satiety, bloating, anorexia, nausea, and vomiting. Aim and Aimsia: Objectives and goals: To determine and compare the efficacy of the latester drugs, levosulpiride and itopride in functional dyspepsia, see Aim and objectives. In follow-up visits at the 2nd and the fourth week from the day of presentation, there was a significant decrease in mean global symptom score and mean duration score, as well as the mean score of severity. In Functional Dyspepsia, Saxena GN, Mathur S. A Randomized Controlled Study of Efficacy and Safety Profile of Levosulpiride and Itopride.

Source link: https://doi.org/10.5005/jp-journals-10057-0131


Dysphagia, dyspepsia, and hiccups

Although patients may experience dysphagia as a result of chronic disease and increasing debilitation, some patients may experience dysphagia as a complication of progressive disease and increasing debilitation. Patients must be suffering one or two of the following four conditions: epigastric pain, epigastric fire, postprandial fullness, or early satiety are all common problems. Dyspepsia may develop either as a medical condition where the cause is unclear or as a secondary condition.

Source link: https://doi.org/10.1093/med/9780198821328.003.0052


Dyspepsia

Dyspepsia is a term that refers to many signs of the upper gastrointestinal tract, including acid reflux, heartburn, nausea, vomiting, and abdominal pain or discomfort. Patients spend over a 3100 million annually, while prescription drugs cost the NHS more than $400,000 per year. Helicobacter pylori is present in 40% of the UK population, with many people acquiring the disease in childhood and remaining asymptomatic.

Source link: https://doi.org/10.1093/med/9780199568741.003.0025

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions